Status:
COMPLETED
Assays for and Reversal of New Anticoagulants
Lead Sponsor:
R.P.Herrmann
Conditions:
Atrial Fibrillation
Osteoarthritis of the Knee
Eligibility:
All Genders
18+ years
Brief Summary
New anticoagulants are being introduced to replace warfarin. These drugs do not require monitoring and are safer. There is currently no recommended way to reverse these drugs rapidly in the event of u...
Detailed Description
We are developing in vitro assays of measurement of the effect of these drugs on the relevant coagulation pathways in plasma; such assays are not widely established. This will then allow us to test po...
Eligibility Criteria
Inclusion
- Receiving dabigatran for atrial fibrillation
- Or,for osteoarthritis of the hip or knee receiving rivaroxaban to prevent thromboembolic disease after total hip or knee replacement respectively
Exclusion
- Failure to sign informed consent
Key Trial Info
Start Date :
April 1 2012
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
April 1 2013
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT01795781
Start Date
April 1 2012
End Date
April 1 2013
Last Update
May 3 2013
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Royal Perth Hospital
Perth, Western Australia, Australia, 6000